Moffitt Cancer Center researchers, led by cancer biologist Eric Lau, demonstrated how L-fucose, a nontoxic dietary plant sugar that is enriched in red and brown seaweeds, can increase tumor infiltrating lymphocytes, promote antitumor immunity, and improve the efficacy of immunotherapy.
Data from the IMROZ phase III trial demonstrated Sarclisa (isatuximab), in combination with standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd) followed by Sarclisa-Rd (the IMROZ regimen), significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with newly-diagnosed multiple myeloma not eligible for transplant.
